Wyszukaj badanie kliniczne
22 Wyniki
Badanie kliniczne z otwartą rekrutacją
= 
; Badanie kliniczne w toku
= 
; Terminated trial = 
; Ufundowane przez członka IRDiRC = 
; MISSING CONTENT = 
Krajowe badania kliniczne
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
An Open-Label Extension Study of the Safety of Relacorilant in the Treatment of the Signs and Symptoms of Cushing Syndrome (Phase II-III) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
GRADIENT: Glucocorticoid Receptor Antagonism in the Treatment of Hypercortisolism in Patients with Cortisol-Secreting Adrenal Adenomas or Hyperplasia: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Relacorilant - AT
Institution: Information not provided - AT
FRANCJA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
ACSPIRE : SPI-62 en traitement de l'hypercortisolisme associé à une tumeur bénigne de la glande surrénale -FR
Institution: Information not provided - FR
NIEMCY
Bayern
WÜRZBURG
ACSPIRE: SPI-62 zur Behandlung von Hyperkortisolismus aufgrund eines gutartigen Nebennierentumors
Zentrum Innere Medizin (ZIM)
Medizinische Klinik und Poliklinik I - Endokrinologie und Diabetologie
WŁOCHY
TOSCANA
PISA
ACSPIRE: SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor - IT
Azienda Ospedaliero Universitaria Pisana - Ospedale Cisanello
U.O. Endocrinologia 2
HOLANDIA
Noord-Holland
AMSTERDAM
The Drug Rediscovery Protocol (DRUP trial): A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile (Phase II)
Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis
Afdeling Maag-Darm-Leveroncologie
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
An Open-label, Multi-center, Roll-over Study to Assess Long Term Safety in Patients With Endogenous Cushing's Syndrome Who Have Completed a Prior Novartis-sponsored Osilodrostat (LCI699) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Osilodrostat (Phase 2) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
GRACE: Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome: A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant - AT
Institution: Information not provided - AT
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STEP: Programme d'extension à long terme du Sorafénib - BE
Cliniques universitaires Saint-Luc - UCLouvain
Pneumologie_Oncologie thoracique
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Een fase II, multicenter, open-label, niet-vergelijkende studie om de farmacokinetiek, farmacodynamiek en verdraagbaarheid van osilodrostat bij kinderen en adolescente patiënten met de ziekte van Cushing te evalueren - BE
Universitair Ziekenhuis Brussel
Endocrinologie
FRANCJA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
An Open Label Study to Assess the Safety and Efficacy of COR-003 (Levoketoconazole) in the Treatment of Endogenous Cushing's Syndrome (Phase III) - FR
Institution: Information not provided - FR
WŁOCHY
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
Studio di fase III in aperto finalizzato alla valutazione della sicurezza e dell'efficacia di COR-003 (2S, 4R-ketoconazolo) nel trattamento della sindrome di Cushing endogena - IT
Institution: Information not provided - IT
WŁOCHY
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
Studio in aperto di fase I/II per valutare la sicurezza, la tollerabilità e l'efficacia preliminare di durvalumab in monoterapia o in combinazione con tremelimumab in pazienti pediatrici con tumori solidi avanzati e neoplasie ematologiche
Institution: Information not provided - IT
WŁOCHY
LAZIO
ROMA
Studio in aperto, a braccio singolo, di fase 1/2 che valuta la sicurezza e l'efficacia di Ponatinib per il trattamento delle leucemie ricorrenti o refrattarie o dei tumori solidi in pazienti pediatrici
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO
U.O. di Oncoematologia
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
GRACE: Antagonismo del receptor de glucocorticoides en el tratamiento del síndrome de Cushing estudio: ensayo en fase III, con doble enmascaramiento, controlado con placebo y con retirada aleatorizada sobre la eficacia y la seguridad del relacorilant -ES
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio de extensión sin enmascaramiento de la seguridad de relacorilant (CORT125134) en el tratamiento de los signos y síntomas del síndrome de Cushing endógeno -ES
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
GRADIENT: Antagonismo del receptor de glucocorticoides en el tratamiento del hipercortisolismo en pacientes con adenomas suprarrenales que secretan cortisol o hiperplasia: Estudio de fase III, aleatorizado, doble ciego y comparado con placebo sobre la eficacia y la seguridad de relacorilant -ES
Institution: Information not provided - ES
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Institution: Information not provided - US
Wieloośrodkowe badania kliniczne
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
ACSPIRE: SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor.
Institution: Information not provided - US
SZWECJA
Region Stockholm
ADDRESS: NOT PROVIDED - SE
An open label study to asses the safety and efficacy of COR-003 (2S, 4R-Ketoconazole) in the treatment of endogenous Cushing's syndrome (phase III)
Institution: Information not provided - SE
SZWAJCARIA
Suisse Romande
ADDRESS: NOT PROVIDED - CH
An open-label, multi-center, roll-over study to assess long term safety inpatients with endogenous Cushingâ??s syndrome who have completed a priorNovartis-sponsored osilodrostat (LCI699) study and are judged by theinvestigator to benefit from continued treatment with osilodrostat. - NA
Institution: Information not provided - CH
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US